These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 33079317)

  • 1. Harm Reduction Works: Evidence and Inclusion in Drug Policy and Advocacy.
    Klein A
    Health Care Anal; 2020 Dec; 28(4):404-414. PubMed ID: 33079317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Principles, practice, and policy vacuums: Policy actor views on provincial/territorial harm reduction policy in Canada.
    Hyshka E; Anderson-Baron J; Pugh A; Belle-Isle L; Hathaway A; Pauly B; Strike C; Asbridge M; Dell C; McBride K; Tupper K; Wild TC
    Int J Drug Policy; 2019 Sep; 71():142-149. PubMed ID: 30711412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Harm reduction as a complex adaptive system: A dynamic framework for analyzing Tanzanian policies concerning heroin use.
    Ratliff EA; Kaduri P; Masao F; Mbwambo JK; McCurdy SA
    Int J Drug Policy; 2016 Apr; 30():7-16. PubMed ID: 26790689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Harm reduction headway and continuing resistance: insights from safe injection in the city of Vancouver.
    Hathaway AD; Tousaw KI
    Int J Drug Policy; 2008 Feb; 19(1):11-6. PubMed ID: 18164610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disagreement, Unenforceability, and Harm Reduction.
    Weinstock DM
    Health Care Anal; 2020 Dec; 28(4):314-323. PubMed ID: 33099712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Civil society involvement in harm reduction drug policy: reflections on the past, expectations for the future.
    O'Gorman A; Schatz E
    Harm Reduct J; 2021 Feb; 18(1):17. PubMed ID: 33568156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Policy actor views on structural vulnerability in harm reduction and policymaking for illegal drugs: A qualitative study.
    Gehring ND; Speed KA; Wild TC; Pauly B; Salvalaggio G; Hyshka E
    Int J Drug Policy; 2022 Oct; 108():103805. PubMed ID: 35907373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. "You need to just provide health services:" navigating the politics of harm reduction in the twin housing and overdose crises in Vancouver, BC.
    Nowell M; Masuda JR;
    Int J Drug Policy; 2020 Aug; 82():102774. PubMed ID: 32512342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The ever-changing narrative: Supervised injection site policy making in Ontario, Canada.
    Ziegler BR; Wray AJ; Luginaah I
    Int J Drug Policy; 2019 Dec; 74():98-111. PubMed ID: 31586776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deconstructing prohibitionist ideology: A sociocognitive approach to understand opinions on UK drug policy and the law.
    Askew R; Bone M
    Int J Drug Policy; 2019 Dec; 74():33-40. PubMed ID: 31454756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 'We are still obsessed by this idea of abstinence': A critical analysis of UK news media representations of proposals to introduce drug consumption rooms in Glasgow, UK.
    Atkinson AM; McAuley A; Trayner KMA; Sumnall HR
    Int J Drug Policy; 2019 Jun; 68():62-74. PubMed ID: 31003193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Harm reduction drug policy in Israel: what has been accomplished and what still needs to be done?
    Bonny-Noach H
    Isr J Health Policy Res; 2019 Oct; 8(1):75. PubMed ID: 31619286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Harm reduction in name, but not substance: a comparative analysis of current Canadian provincial and territorial policy frameworks.
    Hyshka E; Anderson-Baron J; Karekezi K; Belle-Isle L; Elliott R; Pauly B; Strike C; Asbridge M; Dell C; McBride K; Hathaway A; Wild TC
    Harm Reduct J; 2017 Jul; 14(1):50. PubMed ID: 28747183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Canadian harm reduction policies: A comparative content analysis of provincial and territorial documents, 2000-2015.
    Wild TC; Pauly B; Belle-Isle L; Cavalieri W; Elliott R; Strike C; Tupper K; Hathaway A; Dell C; MacPherson D; Sinclair C; Karekezi K; Tan B; Hyshka E
    Int J Drug Policy; 2017 Jul; 45():9-17. PubMed ID: 28454045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How do actors with asymmetrical power assert authority in policy agenda-setting? A study of authority claims by health actors in trade policy.
    Townsend B; Schram A; Labonté R; Baum F; Friel S
    Soc Sci Med; 2019 Sep; 236():112430. PubMed ID: 31351362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Harm reduction interventions in drug users: current situation and recommendations].
    Bosque-Prous M; Brugal MT
    Gac Sanit; 2016 Nov; 30 Suppl 1():99-105. PubMed ID: 27837802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beyond human rights and public health: citizenship issues in harm reduction.
    Chen JS
    Int J Drug Policy; 2011 May; 22(3):184-8. PubMed ID: 21242083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Consumer protection in drug policy: The human rights case for safe supply as an element of harm reduction.
    Csete J; Elliott R
    Int J Drug Policy; 2021 May; 91():102976. PubMed ID: 33041183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stigmatizing harm reduction through language: a case study into the use of "addict" and opposition to supervised injection sites in Canada.
    Cortina SC
    J Addict Nurs; 2013; 24(2):102-7. PubMed ID: 24621488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The social logic of naloxone: Peer administration, harm reduction, and the transformation of social policy.
    Faulkner-Gurstein R
    Soc Sci Med; 2017 May; 180():20-27. PubMed ID: 28315595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.